KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
2021 · The Lancet · 721 citations
https://doi.org/10.1016/s0140-6736(21)01222-8
T
Tong Shen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
188
Papers
3.9K
Citations
29
h-index
61
i10-index
Tong Shen is an academic researcher from Qingdao University of Science and Technology. The author has contributed to research in topics: CAR-T cell therapy research & Drug Transport and Resistance Mechanisms & Acute Lymphoblastic Leukemia research. The author has an h-index of 29, co-authored 160 publications.
ORCID: 0000-0001-8558-2086Papers by this author
worksHuman Multidrug Resistance Protein 7 ( <i>ABCC10</i> ) Is a Resistance Factor for Nucleoside Analogues and Epothilone B
2008 · Cancer Research · 153 citations
https://doi.org/10.1158/0008-5472.can-08-1420
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance
2009 · Biochemical Pharmacology · 98 citations
https://doi.org/10.1016/j.bcp.2009.08.021
Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance
2008 · Biochemical Pharmacology · 75 citations
https://doi.org/10.1016/j.bcp.2008.12.005
Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)
2009 · PLoS ONE · 70 citations
https://doi.org/10.1371/journal.pone.0007520
Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study
2020 · Diabetes Therapy · 31 citations
https://doi.org/10.1007/s13300-020-00845-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat